Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma.
暂无分享,去创建一个
Liang Cheng | A. Lazar | S. Kamel‐Reid | L. Sholl | J. Bridge | T. Gangadhar | A. Andea | Kirtee Raparia | Alan E. Siroy | M. Davies | Mani Ehteshami | Kimberly L Watson
[1] J. Utikal,et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.
[2] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[3] Liang Cheng,et al. Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. , 2014, Human pathology.
[4] A. Lazar,et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma , 2013, Cancer.
[5] A. D. Van den Abbeele,et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Bastian,et al. Targeting activated KIT signaling for melanoma therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] K. Flaherty,et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. O'toole,et al. BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.
[9] Robert N. Anderson,et al. Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.
[10] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[11] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[12] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[13] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[14] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Wisell,et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma , 2013 .
[16] J. Stockman. KIT as a Therapeutic Target in Metastatic Melanoma , 2013 .
[17] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .